Gland Pharma Ltd

Gland Pharma announced that the Annual General Meeting(AGM) of the company will be held on 28 August 2025.Powered by Capital Market - Live

Net profit of Gland Pharma declined 3.06% to Rs 186.54 crore in the quarter ended March 2025 as against Rs 192.42 crore during the previous quarter ended March 2024. Sales declined 7.32% to Rs 1424.91 crore in the quarter ended March 2025 as against Rs 1537.45 crore during the previous quarter ended March 2024. For the full year,net profit declined 9.57% to Rs 698.53 crore in the year ended March 2025 as against Rs 772.46 crore during the previous year ended March 2024. Sales declined 0.85% to Rs 5616.50 crore in the year ended March 2025 as against Rs 5664.72 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1424.911537.45 -7 5616.505664.72 -1 OPM %24.3923.33 -22.5923.53 - PBDT384.09390.84 -2 1440.531477.11 -2 PBT288.33298.23 -3 1062.661132.54 -6 NP186.54192.42 -3 698.53772.46 -10 Powered by Capital Market - Live

Gland Pharma announced that the Board of Directors of the Company at its meeting held on 20 May 2025, inter alia, have recommended the final dividend of Rs 18 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Latanoprostene Bunod Ophthalmic Solution, 0.024%. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VYZULTA Ophthalmic solution, 0.024%, of Bausch and Lomb, Inc. This Product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity. Powered by Capital Market - Live

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc. This product is indicated for the management of mild to moderate pain in adult and pediatric patients aged 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients aged 2 years and older. According to IQVIA, the product had US sales of approximately $55 million for the twelve months ending February 2025. The company expects to launch this product through its marketing partner in the near future. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. Gland Pharma's consolidated net profit increased 6.67% to Rs 204.70 crore despite a 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25. Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Acetaminophen Injection, 10 mg/mL (500mg/50mL and 1000mg/100mL) Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc. This Product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older. The Company expects to launch this Product through its marketing partner in the near future. According to IQVIA, the product had US sales of approximately USD 55 million for the twelve months ending February 2025.Powered by Capital Market - Live

Gland Pharma Ltd gained 9.65% today to trade at Rs 1683.25. The BSE Healthcare index is up 2.92% to quote at 42322.92. The index is up 9.7 % over last one month. Among the other constituents of the index, Marksans Pharma Ltd increased 6.49% and Aurobindo Pharma Ltd added 5.74% on the day. The BSE Healthcare index went up 19.37 % over last one year compared to the 2.98% surge in benchmark SENSEX. Gland Pharma Ltd has added 10.42% over last one month compared to 9.7% gain in BSE Healthcare index and 4.23% rise in the SENSEX. On the BSE, 14825 shares were traded in the counter so far compared with average daily volumes of 8311 shares in the past one month. The stock hit a record high of Rs 2220.95 on 06 Aug 2024. The stock hit a 52-week low of Rs 1412 on 12 Feb 2025.Powered by Capital Market - Live

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1537.85, down 1.01% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.55% on the day, quoting at 23293.85. The Sensex is at 76509.06, up 0.64%.Gland Pharma Ltd has eased around 0.06% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 5.1% in last one month and is currently quoting at 20771.8, up 0.58% on the day. The volume in the stock stood at 36116 shares today, compared to the daily average of 3.73 lakh shares in last one month.The PE of the stock is 22.85 based on TTM earnings ending December 24.Powered by Capital Market - Live

Gland Pharma has appointed Wriddhee Maitra as Vice-President (Human Resources), a Senior Management Personnel of the Company with effect from 10 March 2025.Powered by Capital Market - Live